Clinical Trials Using Epacadostat

Clinical trials are research studies that involve people. The clinical trials on this list are studying Epacadostat. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-15 of 15
  • INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

    The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.
    Location: 4 locations

  • Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

    T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.
    Location: 3 locations

  • Epacadostat and Pembrolizumab in Treating Patients with Imatinib-Refractory Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed by Surgery

    This phase II trial studies how epacadostat and pembrolizumab work in treating patients with gastrointestinal stromal tumors that have spread to other places in the body and do not respond to imatinib or that cannot be removed by surgery. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving epacadostat and pembrolizumab may work better in treating patients with gastrointestinal stromal tumors.
    Location: 2 locations

  • DEC-205 / NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and Epacadostat in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

    This partially randomized phase I / IIb trial studies the side effects and best dose of epacadostat in combination with DEC-205 / NY-ESO-1 fusion protein CDX-1401 and poly ICLC and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer who no longer have evidence of disease. Antigens (such as cancer / testis antigen [NY-ESO-1] protein) are found on many cancer cells. Vaccines made from NY-ESO-1 protein may cause the immune system to produce immune cells and antibodies that may help locate the NY-ESO-1 and / or cancer / testis antigen 2 (LAGE-1) antigens on cancer cells. By finding them, the immune system may then work to control or eliminate the remaining cancer cells. Epacadostat is an inhibitor of an enzyme called indoleamine 2,3 dioxygenase (IDO). This enzyme is produced by tumor cells to disable immune cells, and limit the efficacy of immune attack. Giving DEC-205 / NY-ESO-1 fusion protein CDX-1401 with poly ICLC and epacadostat may generate stronger and more long lasting anti-cancer immune responses in patients with ovarian, fallopian tube, and primary peritoneal cancer in remission.
    Location: 2 locations

  • Phase I / II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)

    Background: Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone. This may be true for many types of cancer, including castration-resistant prostate cancer (mCRPC). Objective: To test if the combination of the drugs BN-brachyury, M7824, ALT-803, and Epacadostat is safe and shrinks tumors. Eligibility: People ages 18 and older with mCRPC or another metastatic cancer Design: Participants will be screened with: - Medical history - Physical exam - CT or MRI scans - Possible bone imaging - Blood, urine, and heart tests - Possible tumor biopsy Participants will be treated with a 2-, 3- or 4-drug combinations of the following study drugs in 2-week cycles: - Participants will receive M7824 by IV once every 2 weeks. - Participants will receive ALT-803 by injection once every 2 weeks. They will record any skin changes at the injection site in a diary. - Participants will receive BN-brachyury as 4 injections to different limbs. They will get the first 3 doses 2 weeks apart. Then they will get doses every 4 weeks for 6 months, then every 3 months for 2 years, then every 6 months. - Participants will take Epacadostat orally every 12 hours. They will keep a pill diary. Participants will have physical exams and blood and urine tests at the start of each cycle. They may have scans every 12 weeks. Participants will continue treatment until their disease gets worse or they cannot tolerate the side effects. Participants will have a follow-up visit 4-5 weeks after they stop treatment. They will have a physical exam and blood tests. They may be asked to return for scans every 3 months.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Epacadostat in Treating Patients with Resectable Solid Tumors

    This phase Ib trial studies how epacadostat reacts in the body and how well it works in treating patients with solid tumors that can be removed by surgery. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Epacadostat and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Sarcoma

    This phase II trial studies how well epacadostat and pembrolizumab work in treating patients with sarcoma that has spread to nearby tissues, lymph nodes or other places in the body. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving epacadostat and pembrolizumab may work better in treating patients with sarcoma.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Epacadostat, Toll-Like Receptor 9 Agonist SD-101, and Radiation Therapy in Treating Participants with Advanced, Metastatic, or Refractory Solid Tumors or Lymphoma

    This phase I / II trial studies the side effects and best dose of epacadostat when given together with toll-like receptor 9 agonist SD-101 and radiation therapy work in treating participants with solid tumors or lymphoma that has spread to other places in the body or does not respond to treatment. Epacadostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as toll-like receptor 9 agonist SD-101, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving epacadostat, toll-like receptor 9 agonist SD-101, and radiation therapy may work better in treating participants with solid tumors or lymphoma.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Epacadostat, Pembrolizumab, and CRS-207 with or without Cyclophosphamide and a Vaccine (GVAX Pancreas Vaccine) in Treating Patients with Metastatic Pancreatic Cancer

    This phase II trial studies the side effects and best dose of epacadostat and to see how well it works when given together with pembrolizumab and CRS-207 with or without cyclophosphamide and GVAX pancreas vaccine in treating patients with pancreatic cancer that has spread to other places in the body. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CRS-207 may cause the immune system to attack cells with mesothelin, which may then kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Proteins in GVAX pancreas vaccine may help to activate the immune system cells (the body’s system to fight infection or disease) to recognize and attack cancer cells. It is not yet known whether given epacadostat, pembrolizumab, and CRS-207 with cyclophosphamide and GVAX pancreas vaccine works better in treating patients with pancreatic cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Pembrolizumab and Epacadostat in Treating Participants with Advanced Thymic Cancer

    This phase II trial studies how well pembrolizumab and epacadostat works in treating participants with thymic cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and epacadostat may work better in treating participants with advanced thymic cancer.
    Location: 3 locations

  • Tavokinogene Telseplasmid with Electroporation, Pembrolizumab, and Epacadostat in Treating Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck

    This phase II trial studies how well tavokinogene telseplasmid with electroporation, pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by surgery. Tavokinogene telseplasmid with electroporation is a gene therapy that may delay of tumor growth and which may have less toxicity than other methods of gene delivery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tavokinogene telseplasmid with electroporation, pembrolizumab, and epacadostat may work better in treating squamous cell carcinoma of the head and neck.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Epacadostat with Standard Chemoradiation Therapy before Surgery in Treating Patients with Locally Advanced Rectal Cancer

    This phase I trial studies the side effects and best dose of epacadostat when given together with standard cheotherapy and radiation therapy (chemoradiation) before surgery in treating patients with rectal cancer that has spread to nearby tissues and lymph nodes. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving epacadostat in addition to standard chemoradiation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Pembrolizumab and Epacadostat in Treating Participants with Squamous Cell Carcinoma of the Head and Neck before Surgery

    This phase II trial studies how well pembrolizumab and epacadostat work in treating participants with squamous cell carcinoma of the head and neck before surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and epacadostat may work better in shrinking tumors to the degree that surgery may be easier or more successful and potentially avoid additional or lesson side effects of standard of care treatments.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Pembrolizumab and Epacadostat in Treating Patients with Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma

    This phase II trial studies how well pembrolizumab and epacadostat work in treating patients with ovarian clear cell carcinoma that has come back, remains despite treatment, or is growing, spreading, or getting worse. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and epacadostat may work better in treating patients with ovarian clear cell carcinoma.
    Location: 360 locations

  • Epacadostat and Sirolimus in Treating Participants with Advanced Cancer

    This phase I trial studies the side effects and best dose of epacadostat and sirolimus in treating participants with cancer that has spread to other places in the. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as sirolimus, is used to decrease the body’s immune response and may increase blood cell count. Giving epacadostat and sirolimus may work better at treating advanced cancer.
    Location: 6 locations